Law Offices of Thomas J. Lamb

  • Free Case Evaluation
  • Mesothelioma & Asbestos Diseases
  • Legal Compensation
  • Asbestos Overview
  • Common Questions
  • About Our Firm

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

February 21, 2022 By Thomas Lamb

Background: In the phase 3 CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma [(unresectable MPM)]. We report updated data with 3-year minimum follow-up. Patients and methods: Adults with previously … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Nivolumab

Nivolumab plus ipilimumab confers sustained OS benefit in malignant pleural mesothelioma

December 15, 2021 By Thomas Lamb

Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma, according to randomized phase 3 trial data released by the manufacturer. The open-label, multicenter CheckMate-743 trial included 605 patients who received six cycles of pemetrexed and … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Nivolumab

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

November 3, 2021 By Thomas Lamb

Background:  No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab, an anti-PD-1 antibody, in these patients. Methods:  This was a multicentre, … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant mesothelioma, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Nivolumab, peritoneal malignant mesothelioma

Immunotherapy combination maintains OS advantage in malignant pleural mesothelioma

October 28, 2021 By Thomas Lamb

The combination of nivolumab and ipilimumab maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results. Researchers observed the benefit of the first-line immunotherapy regimen despite patients having been off … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Nivolumab, Opdivo, Yervoy

Nivo/Ipi Combo Now ‘Standard of Care’ in Mesothelioma

October 12, 2021 By Thomas Lamb

The [ combination immunotherapy consisting ] of nivolumab (Opdivo) and ipilimumab (Yervoy) offers a durable, long-term survival benefit over chemotherapy for patients with unresectable malignant pleural mesothelioma (MPM), confirms a 3-year updated analysis of the CheckMate 743 trial. After 3 years, 23% of patients who received combination … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: combination immunotherapy, Ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Nivolumab, Opdivo, Yervoy

Nivolumab prolongs PFS, OS in relapsed malignant mesothelioma

April 29, 2021 By Thomas Lamb

Nivolumab significantly prolonged PFS and OS compared with placebo for patients with [ relapsed mesothelioma ], according to findings presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer. “Mesothelioma is predominately a disease that is not suitable for surgery and is one for which chemotherapy has … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, Nivolumab, Opdivo

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

February 16, 2021 By Thomas Lamb

Background:  Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have moderate survival benefit with poor outcomes. Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, including first-line non-small-cell lung cancer. We hypothesised that this regimen would … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, Ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Nivolumab

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Main Navigation Menu

  • Who Was Exposed to Asbestos
  • NC Asbestos Exposure Sites
  • Asbestos-Contaminated Talc
  • Asbestos Diseases
  • Legal Compensation
  • Free Case Evaluation
  • Frequently Asked Questions
  • About Our Law Firm
  • Attorney Tom Lamb
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

TJL@LambLawOffice.com

Phone: 800-426-9535

Lumina Station, Suite 225
1908 Eastwood Road
Wilmington, North Carolina

Please know that you can use our Quick Contact Form to tell us about your case.

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Website

Lamb Law Office

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.